Background {#section22-2054358118801017}
==========

N-acetyl cysteine (NAC) is an antioxidant which can regenerate glutathione and is primarily used for acetaminophen overdose.^[@bibr1-2054358118801017]^ However, it has also been tested in prevention of acute kidney injury (AKI) in different settings, such as postoperative AKI and contrast induced AKI (CI-AKI) with mixed results, mainly using change in serum creatinine levels before and after NAC treatment as the outcome. Nevertheless, given the low cost and lack of side effects, NAC has been recommended for use by the Kidney Disease Improving Global Outcomes (KDIGO) guidelines in the context of CI-AKI.^[@bibr2-2054358118801017]^ Additionally, although NAC is generally recommended for patients with chronic kidney disease (CKD), with an eGFR \<60 ml/min/1.73 m^2^ in clinical practice, the supporting evidence has been inadequate.^[@bibr2-2054358118801017]^ A recent systematic review from the Agency for Healthcare Research and Quality (AHRQ) also supports its use for CI-AKI prophylaxis.^[@bibr3-2054358118801017]^ At present, there are over 20 ongoing trials testing the efficacy of NAC for prevention of acute kidney injury (AKI) in various settings (contrast AKI, perioperative AKI, drug-induced AKI) as well as in CKD for slowing progression or preserving residual kidney function.^[@bibr4-2054358118801017]^ Therefore, a significant body of research is in progress and the outcome of these large and expensive trials may quantitatively resolve the effectiveness of NAC for preventing CI-AKI. Notably, a biological mechanism or rationale for a protective effect of NAC has never been satisfactorily reported.^[@bibr5-2054358118801017]^

Among conflicting reports, there appears to be evidence that NAC may artificially lower measured serum creatinine without improving kidney function, by interference with the enzymatic laboratory test.^[@bibr6-2054358118801017],[@bibr7-2054358118801017]^ If a dose of medication or some other treatment reduces serum creatinine levels via interference, this may incorrectly be interpreted as representing increased kidney excretion and improved organ functioning.

Given these mixed results, a systematic review of the literature will be conducted to determine the effect of N-acetylcysteine (NAC) on serum creatinine. The review methodology, as described below, is designed to tease out potential nuances regarding characteristics of the patient population, NAC route of administration, and measurement of kidney function biomarkers.

Methods {#section23-2054358118801017}
=======

Study Design {#section24-2054358118801017}
------------

The specific objectives are to summarize available evidence on direct effect of NAC, through various routes of administration without dose limitation, on kidney function as measured by serum creatinine.

This systematic review will be performed to determine whether there is a direct effect of NAC on serum creatinine. It will adhere to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement, using the Cochrane Risk of Bias (RoB) 2.0 tool for individually randomized, parallel group trials, and the Newcastle-Ottawa Scale (NOS) for observational studies for quality assessment.^[@bibr8-2054358118801017],[@bibr9-2054358118801017]^ This protocol is reported in accordance with the PRISMA-P 2015 checklist (see [Supplementary Material](http://journals.sagepub.com/doi/suppl/10.1177/2054358118801017)).

Eligibility Criteria {#section25-2054358118801017}
--------------------

### Type of studies {#section26-2054358118801017}

This systematic review will consider all studies exploring of the potential effect of NAC on human kidney function as quantified by baseline and follow-up serum creatinine and/or serum cystatin C measurements. Randomized controlled trials, crossover randomized controlled trials, and prospective before/after NAC dose single-arm protocols will be included. Existing systematic reviews and meta-analyses will be excluded, but their bibliographies and more-recent citing articles will be cross-referenced to strengthen our literature search. Studies that are not clinical trials (e.g. observational study, case series) will be excluded. Studies without outcome measures (e.g. serum creatinine, cystatin C) will be excluded. Trials of using NAC as a protective agent to prevent AKI (eg, CI-AKI or postoperative AKI) will also be excluded.

### Patient population {#section27-2054358118801017}

This review will consider prospective clinical trial studies of adult humans aged 18 years old or more, receiving NAC with prior and subsequent serum measurement creatinine and/or cystatin C. The patient population will include healthy volunteers or CKD patients, defined as the presence of kidney damage (urinary albumin excretion of ⩾ 30 mg/day) or decreased kidney function (estimated glomerular filtration rate \<60 mL/min/1.73m^2^). Patients with minimal to none kidney function, for example, end-stage kidney disease (ESKD), and/or those requiring renal replacement therapy such as dialysis or transplantation will be excluded. Patient populations receiving contrast agents and those simultaneously undergoing surgery will be excluded from the study to avoid potential for kidney function due to CI-AKI or other acute kidney injury.

### Intervention {#section28-2054358118801017}

The exposure to be assessed is NAC (oral administration and/or intravenous injection, without restriction on dose).

### Comparator {#section29-2054358118801017}

For randomized controlled trials, patients receiving NAC will be compared to those receiving placebo. For single-arm prospective cohort studies, data on change in creatinine from baseline (i.e. before and after NAC administration) will be extracted.

Information Sources and Search Strategy {#section30-2054358118801017}
---------------------------------------

A comprehensive systematic search will be performed using standard electronic databases including MEDLINE, EMBASE, and the Cochrane CENTRAL Library. Databases will be searched in all available time, from the oldest literature to the search date (1947 to July 2018). An information scientist (AD) will help design the search strategy and conduct the search (see [Table 1](#table1-2054358118801017){ref-type="table"} for preliminary strategy). Cross-reference bibliographies and citations of published works will be conducted to identify additional potential studies. Non-English literatures will be excluded.

###### 

MEDLINE Search Strategy.

![](10.1177_2054358118801017-table1)

  Medline Search Algorithm
  ----------------------------------------------------------------------------------------------
  1\. Acetylcysteine/
  2\. (acetylcysteine or n-acetylcysteine or n-acetyl cysteine).tw,kw.
  3\. 1 or 2
  4\. exp Kidney Function Tests/ or ((renal or kidney) adj2 function\$).tw,kw.
  5\. Creatinine/ or Cystatin C/ or Urea/
  6\. (creatinine or urea or albumin or cystatin c or gfr or glomerular filtration rate\$).tw.
  7\. or/4-6
  8\. 3 and 7
  9\. Prospective Studies/
  10\. prospective\$.tw.
  11\. randomized controlled trial.pt.
  12\. controlled clinical trial.pt.
  13\. randomi?ed.ab.
  14\. placebo.ab.
  15\. clinical trials as topic.sh.
  16\. randomly.ab.
  17\. trial.ti.
  18\. or/9-17
  19\. 8 and 18

Study Records {#section31-2054358118801017}
-------------

### Data management and selection process {#section32-2054358118801017}

Pertinent articles identified by our search strategy will be reviewed systematically. Two authors (O.J.C., J.W.H.) will independently screen abstracts, and remove studies clearly meeting exclusion criteria in a first-round of analysis. Articles not excluded outright via abstract analysis will be downloaded as full-text documents and scrutinized again in a second review stage (by O.J.C., J.W.H.) for inclusion/exclusion criteria ([Table 2](#table2-2054358118801017){ref-type="table"}). Any disagreement regarding article inclusion will be solved by in-person meeting to attempt consensus and if necessary will be forwarded to a third reviewer (S.H.) for adjudication.

###### 

Inclusion and Exclusion Criteria for Our Systematic Review.

![](10.1177_2054358118801017-table2)

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
      Include                                                                                                                                                 Exclude
  --- ------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------
  1   Article type: Prospective Clinical Trials                                                                                                               Other article types

  2   Intervention: NAC (oral or intravenous, all doses)                                                                                                      NAC not used in this manner

  3   Comparator: Placebo or no comparator (eg, single group only receiving NAC)                                                                              

  4   Population: Human adults, healthy volunteers and chronic kidney disease patients                                                                        End-stage kidney disease, pediatric, animal-model studies\
                                                                                                                                                              Use of NAC for prophylaxis (eg, contrast imaging, surgery)

  5   Follow-up: no restriction                                                                                                                               

  6   Outcome: change in kidney function measured by serum creatinine and/or serum cystatin C, compared to baseline or between groups if placebo-controlled   Kidney function not evaluated via either serum creatinine or serum cystatin C

  7   Language: English                                                                                                                                       

  8   Time period: search databases through 1947 to July 2018                                                                                                 
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Note.* NAC = N-acetylcysteine.

### Data collection process {#section33-2054358118801017}

A data extraction template will be created by the principal investigator (S.H.) in Microsoft Excel and modified by feedback from two independent reviewers (O.J.C. and J.W.H.) to ensure that complete data is obtained. O.J.C. and J.W.H. will perform data extraction from selected manuscripts and compare for consistency. In cases with disagreement, consensus will be attempted via further discussion, and input by a third reviewer (S.H.) if necessary. Reviewers will not be blinded to the authors or journals during this process.

Data Items {#section34-2054358118801017}
----------

Data extraction will proceed for the selected studies after secondary screening. The following data will be extracted for analysis---"human" factors related to the manuscripts (research group, country of origin, year of publication, and funding source), study design (Randomized Control Trial \[RCT\], crossover RCT, before/after single arm), patient population (healthy volunteers vs CKD, sample sizes, sex, age, presence of other comorbid conditions such as diabetes), NAC details (oral vs intravenous, dose (total and frequency), control group (placebo-controlled vs no medicine), and kidney-function serum biomarker measurements (creatinine and/or cystatin C, pre-NAC + controls baseline levels vs post-NAC + controls follow-up measurements, and follow-up times), methods used for measuring the biomarkers (Jaffe vs enzymatic creatinine), and associated statistical quantities such as significance (*P* values) and precision (confidence intervals). If the methodology is not clear, authors will be contacted for further information. Lastly, cointerventions and adverse events will serve as other variables for data extraction.

Outcomes and Prioritization {#section35-2054358118801017}
---------------------------

The outcome of interest will include kidney function as reported by either change in serum creatinine and/or serum cystatin C measurement for randomized trials or comparing baseline (pre-NAC dose) values and those following the NAC dose.

ROB in Individual Studies {#section36-2054358118801017}
-------------------------

The explicit aim of our systematic review will be to objectively determine whether there is a direct effect of NAC on human kidney function, in the absence of concomitant kidney injury. Therefore, this study will assess whether the design and implementation of studies included in our review meet quality standards required to infer association between controlled NAC administration and measured kidney function biomarkers (serum creatinine and/or cystatin C). Quality of studies and potential for biases will be examined independently by two authors (O.J.C. and J.W.H.) using standard tools such as Cochrane "Risk of Bias" for randomized studies^[@bibr9-2054358118801017]^ and NOS for observational studies.^[@bibr8-2054358118801017]^ A table comprised of study characteristics will illustrate the results from this methodology quality assessment.

Data Synthesis {#section37-2054358118801017}
--------------

If data heterogeneity, methodological quality, and apparent study biases are of sufficient quality to allow it, data will be pooled from the included studies into a meta-analysis using the Comprehensive Meta-analysis (Biostat Inc. Version 3 Engleside, NJ). The weighted mean difference will be calculated for change in creatinine with NAC, using random-effects analysis. Cochran's Q and I2 statistics will be conducted to assess data homogeneity regarding the effect of NAC administration on kidney function biomarkers. If there is significant statistical heterogeneity, it will be explored with subgroup analysis and univariate meta-regression. Correction factor for multiple comparisons will be considered in the event of missing outcome measurements, when applicable.

Meta-Bias Assessment {#section38-2054358118801017}
--------------------

Additional analyses that will be performed include sensitivity and univariate meta-regression analyses to assess the effects of clinical factors (dose of NAC) and sociodemographic (proportion of diabetes) characteristics reported in included studies on the meta-analyses estimates. Subgroup analyses will be conducted based on route of NAC (oral versus intravenous), method of creatinine measurement (Jaffe vs non-Jaffe methods). Funnel plot methodology, utilizing visualization of the asymmetry and Egger's statistics, will be used to identify publication bias.^[@bibr10-2054358118801017]^

Discussion {#section39-2054358118801017}
==========

There has been much research activity investigating potential protective effects of NAC on kidney function. There is considerable heterogeneity when meta-analyes are conducted, and overall the last quantitative synthesis reports a benefit with NAC use in CI-AKI, but a large subsequent trial found no such benefit. Clearly there is a need for an analysis of the direct effects, if any, of NAC on kidney function for studies considering direct effect of NAC,^[@bibr7-2054358118801017],[@bibr11-2054358118801017][@bibr12-2054358118801017][@bibr13-2054358118801017][@bibr14-2054358118801017]-[@bibr15-2054358118801017]^ with the present systematic review being the first such article to our knowledge. The current practice guidelines^[@bibr2-2054358118801017]^ suggest NAC be used as an oral prophylactic agent among patients at increased risk of CI-AKI, but admittedly on imperfect evidence with the low cost and lack of apparent side effects weighing heavily in this advocacy. While NAC may be relatively inexpensive on a per-dose basis, the cost associated with using it routinely and in large quantities in the clinical acute and chronic kidney injury setting is enormous. Additionally, if there is assay interference, this aspect should be taken into account when using NAC in clinical practice and assessing kidney function.

This systematic review will provide clinicians with strong foundational evidence on which to gauge the effectiveness of NAC on adult kidney function, and whether or not standard clinical practice requires change in the setting of preventing AKI via administration of NAC.

Supplemental Material {#section40-2054358118801017}
=====================

###### PRISMA_P\_checklist_04202018 -- Supplemental material for The Effect of N-Acetylcysteine on Creatinine Measurement: Protocol for a Systematic Review

###### 

Click here for additional data file.
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